Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Antimicrobial Agents and Chemotherapy
David R SnydmanJ A Sutcliffe

Abstract

The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.

References

Nov 26, 2003·Antimicrobial Agents and Chemotherapy·Sean R ConnellDiane E Taylor
Sep 29, 2004·The Journal of Biological Chemistry·Wangrong YangGerard D Wright
Oct 11, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P A BradfordC H Jones
Jan 14, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David R SnydmanSherwood L Gorbach
Feb 23, 2012·Antimicrobial Agents and Chemotherapy·Trudy H GrossmanJoyce A Sutcliffe
Aug 28, 2013·Antimicrobial Agents and Chemotherapy·J A SutcliffeT H Grossman
Apr 6, 2016·Antimicrobial Agents and Chemotherapy·David M LivermoreNeil Woodford
Aug 24, 2016·Antimicrobial Agents and Chemotherapy·Corey FyfeTrudy H Grossman

❮ Previous
Next ❯

Citations

Sep 13, 2018·Expert Review of Anti-infective Therapy·Matteo BassettiAlessandro Russo
Jul 3, 2019·Journal of Clinical Medicine·Nicola PetrosilloGuido Granata
Oct 18, 2019·Expert Review of Anti-infective Therapy·Philippe MontraversAlexy Tran-Dinh
Jan 17, 2020·Pharmacotherapy·Sara AlosaimyMichael J Rybak
Apr 23, 2019·Expert Review of Anti-infective Therapy·Georgios L VoulgarisMatthew E Falagas
Aug 31, 2019·Future Microbiology·Lyudmila BoyanovaIvan Mitov
May 15, 2020·Clinical Microbiology Reviews·David M P De OliveiraMark J Walker
May 3, 2019·Clinical Pharmacokinetics·Matthew W McCarthy
Oct 9, 2019·Expert Opinion on Emerging Drugs·Matteo BassettiMark Wilcox
Jul 29, 2020·The Journal of Antimicrobial Chemotherapy·Eugénie BassèresKevin W Garey
Oct 31, 2020·International Journal of Antimicrobial Agents·Sarrah BoukthirVincent Cattoir
Jan 29, 2021·Journal of Global Antimicrobial Resistance·Sebastian Martin Michael RongCatalina-Suzana Stingu
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Marco TerreniMassimo Pregnolato
Dec 8, 2021·Expert Review of Anti-infective Therapy·Lucrezia BottalicoLuigi Santacroce

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.